Sign in Subscribe
Pharmaceutical industry

Vytorin: A Dual-Action Cholesterol-Lowering Medication

Strategic Insights

— 1 min read

Vytorin, a cholesterol-lowering medication developed by Merck & Co and Schering-Plough, has been approved by the US FDA for the treatment of low-density lipoprotein cholesterol in patients with primary hypercholesterolemia or mixed hyperlipidemia. This medication combines the blockbuster Zocor (simvastatin) and Zetia (ezetimibe) in a dual-action approach, inhibiting both cholesterol production in the liver and absorption in the intestine. The recommended starting dose in the USA is 10mg ezetimibe/20mg simvastatin. Clinical trials have shown that Vytorin is more effective at reducing LDL-C than Pfizer's Lipitor.

Key Takeaways:

  • Vytorin is a dual-action cholesterol-lowering medication approved by the US FDA for the treatment of low-density lipoprotein cholesterol.
  • The medication comprises Merck's Zocor (simvastatin) and Zetia (ezetimibe) and works by inhibiting both cholesterol production in the liver and absorption in the intestine.
  • The recommended starting dose of Vytorin in the USA is 10mg ezetimibe/20mg simvastatin.
  • Clinical trials have shown that Vytorin is more effective at reducing LDL-C than Pfizer's Lipitor, with a 50% reduction in LDL-C compared to a 37% reduction seen with atorvastatin.
  • Vytorin has been licensed in Mexico and Germany, where it is known as Inegy.
  • The product was cleared by the US FDA at the end of 2002.
  • The New Drug Application for Vytorin contained data from a range of clinical trials, including a 24-week study that demonstrated the efficacy of the medication.

Statistics:

  • The recommended starting dose of Vytorin is 10mg ezetimibe/20mg simvastatin in the USA.
  • Clinical trials have shown that Vytorin is more effective at reducing LDL-C than Pfizer's Lipitor, with a 50% reduction in LDL-C compared to a 37% reduction seen with atorvastatin.
  • The product was cleared by the US FDA at the end of 2002.
  • A 24-week study demonstrated the efficacy of the medication in reducing LDL-C.
  • Vytorin has been licensed in Mexico and Germany.

Sources:

  • Marketletters (no date listed)
  • Marketletters (no date listed)
  • Marketletters (no date listed)

Read more